Novartis share price has plunged 4% and is presently trading at Rs 1,119.0.
Meanwhile, the BSE HEALTHCARE index is at 38,536.8 (up 0.1%).
Among the top losers in the BSE HEALTHCARE index today are Glenmark Pharma (down 1.2%) and GRANULES INDIA (down 0.9%).
GSK Pharma (up 3.2%) and SUVEN PHARMACEUTICALS (up 2.2%) are among the top gainers today.
Over the last one year, Novartis has moved up from Rs 903.6 to Rs 1,119.0, registering a gain of Rs 215.4 (up 23.8%).
On the other hand, the BSE HEALTHCARE index has moved up from 26,477.4 to 38,536.8, registering a gain of 45.5% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Glenmark Pharma (up 96.1%), Lupin (up 94.5%) and GSK Pharma (up 92.8%).
Dear Reader: If You Invest in Midcap Stocks, this is for You
The BSE Sensex is at 80,579.1 (up 0.1%).
The top gainers among the BSE Sensex today are Ultratech Cement (up 1.5%) and M&M (up 1.2%). The most traded stocks in the BSE Sensex are Tata Steel and NTPC.
In the meantime, NSE Nifty is at 24,516.5 . Eicher Motor and Ultratech Cement are among the top gainers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 67,097.4 to 80,579.1, registering a gain of 13,481.7 points (up 20.1%).
Novartis net profit fell 41.3% YoY to Rs 147 million for the quarter ended March 2024, compared to a profit of Rs 250 million a year ago. Net sales rose 6.6% to Rs 812 million during the period as against Rs 761 million in January-March 2023.
For the year ended March 2024, Novartis reported 17.6% decrease in net profit to Rs 852 million compared to net profit of Rs 1,034 million during FY23. Revenue of the company fell 11.5% to Rs 3,351 million during FY24.
The current Price to earnings ratio of Novartis, based on rolling 12 month earnings, stands at 32.4.
Equitymaster requests your view! Post a comment on "Novartis Plunges 4%; BSE HEALTHCARE Index Up 0.1%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!